Solid Biosciences Inc.
Clinical trials sponsored by Solid Biosciences Inc., explained in plain language.
Solid Biosciences Inc.
SLDB
NASDAQ
A gene therapy company focused on neuromuscular diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Gene therapy trial aims to slow duchenne muscular dystrophy in boys Results expected Oct 2026 (estimated)
- Gene therapy trial aims to stop duchenne in its tracks Results expected May 2027 (estimated)
- Gene therapy trial aims to tame deadly heart rhythms Results expected Jun 2027 (estimated)